Discussion:
The fall in median LVEF values from baseline to post-treatment was negligible and asymptomatic in
all four studies. The treatment gave good response in all four trials. All studies showed reduced
cardiotoxicity as compared to a previous study by Slamon, et al. (2001), which had 27% of its patients
experiencing life threatening cardiotoxicity. This review gives hope for future research in the
application of liposomal technology in other chemotherapeutic drugs.
Conclusion:
Liposomal doxorubicin with trastuzumab is an effective treatment for HER-2 positive breast cancer
patients with reduced cardiotoxicity that are consistent with reduced systemic distribution.